Evidence map›Paper›PMID 30518655›Full record

ArticleJournal of virology2019

Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

J Brian Kimble, Delphine C Malherbe, Michelle Meyer, Bronwyn M Gunn, Marcus M Karim, Philipp A Ilinykh, Mathieu Iampietro, Khaled S Mohamed, Surendra Negi, Pavlo Gilchuk and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. A Single-Dose Intranasal Combination Panebolavirus Vaccine.The Journal of infectious diseases · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

J Brian Kimble *Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Delphine C Malherbe *Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Michelle MeyerDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Bronwyn M GunnRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Marcus M KarimRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Philipp A IlinykhDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Mathieu IampietroDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Khaled S MohamedDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Surendra NegiDepartment of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, Texas, USA.
Pavlo GilchukVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kai HuangDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Yuri I WolfNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Werner BraunDepartment of Biochemistry and Molecular Biology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, Texas, USA.
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-0049-1079
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA alexander.bukreyev@utmb.edu.
Galveston College · USRagon Institute of MGH, MIT and Harvard · USThe University of Texas Medical Branch at Galveston · USVanderbilt University Medical Center · USNational Institutes of Health · US

Funding

Supplemental Research Project (SRP)U19AI109711 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2014 to 2018
$26.6M
Role of LANA-RBP-jk During Early KSHV InfectionP01CA174439 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2013 to 2018
$8.7M
Shared Resources CoreU54CA190158 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2014 to 2023
$4.2M
Broadly Specific Needle-Free Vaccines against Emerging and Biothreat VirusesR01AI102887 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER · 2013 to 2017
$3.5M
NCI NIH HHS P01 CA174439NCI NIH HHS U54 CA190158NIAID NIH HHS R01 AI102887NIAID NIH HHS U19 AI109711
6 · The paper itself

Abstract

Ebolaviruses Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) cause human disease with high case fatality rates. Experimental monovalent vaccines, which all utilize the sole envelope glycoprotein (GP), do not protect against heterologous ebolaviruses. Human parainfluenza virus type 3-vectored vaccines offer benefits, including needle-free administration and induction of mucosal responses in the respiratory tract. Multiple approaches were taken to induce broad protection against the three ebolaviruses. While GP consensus-based antigens failed to elicit neutralizing antibodies, polyvalent vaccine immunization induced neutralizing responses to all three ebolaviruses and protected animals from death and disease caused by EBOV, SUDV, and BDBV. As immunization with a cocktail of antigenically related antigens can skew the responses and change the epitope hierarchy, we performed comparative analysis of antibody repertoire and Fc-mediated protective mechanisms in animals immunized with monovalent versus polyvalent vaccines. Compared to sera from guinea pigs receiving the monovalent vaccines, sera from guinea pigs receiving the trivalent vaccine bound and neutralized EBOV and SUDV at equivalent levels and BDBV at only a slightly reduced level. Peptide microarrays revealed a preponderance of binding to amino acids 389 to 403, 397 to 415, and 477 to 493, representing three linear epitopes in the mucin-like domain known to induce a protective antibody response. Competition binding assays with monoclonal antibodies isolated from human ebolavirus infection survivors demonstrated that the immune sera block the binding of antibodies specific for the GP glycan cap, the GP1-GP2 interface, the mucin-like domain, and the membrane-proximal external region. Thus, administration of a cocktail of three ebolavirus vaccines induces a desirable broad antibody response, without skewing of the response toward preferential recognition of a single virus.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCell LineDrug CombinationsEbola VaccinesEbolavirusEpitopesFemaleFerretsGenetic VectorsGlycoproteinsGuinea PigsHemorrhagic Fever, EbolaParainfluenza Virus 3, HumanAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralDrug CombinationsEbola Vaccinesenvelope glycoprotein, Ebola virusEpitopesGlycoproteinsViral Envelope ProteinsViral Vaccinesantibody repertoireEbola virusimmune responseimmunizationneutralizing antibodies

Identifiers

PMID30518655
PMCPMC6364037
OpenAlexW2903550245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.